Robert R Kule, MD
Ophthalmology · San Mateo
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 21
- 6 carriers
- Offices
- 2
Offices
2 locations · A Sydney Williams and Associates Inc · Thomas Tayeri M D Inc
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
21 plans · 6 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kule’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
21 of 21 plans
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A118454 · Current
Licensed to practise in California · since 2011 · expires 2027-03-31 · New York University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$116,277
Medicare paid this office $116,277 for 366 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Established patient problem focused exam of visual system | 315 | $71,055 | $80 |
| Exam of visual field with extended testing | 247 | $15,591 | $62 |
| Imaging of optic nerve | 251 | $8,513 | $32 |
| Established patient complete exam of visual system | 52 | $6,351 | $111 |
| New patient visit (45+ min) | 21 | $3,150 | $150 |
See all 9 services
| Established patient problem focused exam of visual system | 315 | $71,055 | $80 |
| Exam of visual field with extended testing | 247 | $15,591 | $62 |
| Imaging of optic nerve | 251 | $8,513 | $32 |
| Established patient complete exam of visual system | 52 | $6,351 | $111 |
| New patient visit (45+ min) | 21 | $3,150 | $150 |
| Return visit (30+ min) | 18 | $1,355 | $75 |
| Exam of the internal drainage system of eye | 37 | $1,027 | $25 |
| Photography of the retina | 16 | $417 | $26 |
| Ultrasound scan of cornea to determine thickness | 20 | $206 | $10 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Who their Medicare patients are
366 Original Medicare patients in 2024. Average age 78 · Women 57% · Also on Medicaid 11% · Health risk score 1.00. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 66% · Diabetes 22% · Chronic kidney disease 19% · Coronary heart disease 18% · Cancer 17% · Atrial fibrillation 15% · Heart failure 11% · Depression 11% · COPD 5% · Dementia 4% · Stroke 4%.
The office billed $350,560, Medicare allowed $163,200 and paid $116,277; for 1,637 services of 20 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 366 | 1,637 | 78 | 1.00 | $350,560 | $116,277 |
| 2023 | 390 | 1,775 | 78 | 0.92 | $389,126 | $129,292 |
| 2022 | 437 | 1,993 | 78 | 0.97 | $446,546 | $147,835 |
| 2021 | 423 | 1,858 | 77 | 0.85 | $415,448 | $140,198 |
| 2020 | 350 | 1,428 | 77 | 1.00 | $355,917 | $123,055 |
| 2019 | 426 | 1,868 | 77 | 0.95 | $434,806 | $156,971 |
| 2018 | 281 | 1,272 | 77 | 1.03 | $258,597 | $100,822 |
| 2017 | 347 | 1,136 | 76 | 1.08 | $246,860 | $97,562 |
| 2016 | 243 | 848 | 77 | 1.15 | $225,679 | $86,262 |
| 2015 | 276 | 556 | 76 | 1.11 | $102,325 | $44,235 |
| 2014 | 79 | 96 | 74 | 1.16 | $20,431 | $4,653 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Established patient problem focused exam of visual system | 331 | $71,110 | $79 |
| Exam of visual field with extended testing | 267 | $15,808 | $57 |
| Imaging of optic nerve | 255 | $8,714 | $31 |
| Return visit (30+ min) | 64 | $7,241 | $105 |
| New patient visit (45+ min) | 39 | $5,306 | $136 |
| Established patient complete exam of visual system | 33 | $3,952 | $116 |
| Exam of the internal drainage system of eye | 49 | $1,398 | $25 |
| Measurement of corneal curvature and depth of eye | 20 | $787 | $37 |
| Photography of the retina | 16 | $537 | $34 |
| Ultrasound scan of cornea to determine thickness | 27 | $289 | $10 |
2022: 11 services
| Established patient problem focused exam of visual system | 354 | $67,214 | $76 |
| Exam of visual field with extended testing | 300 | $17,755 | $57 |
| New patient visit (45+ min) | 71 | $9,750 | $137 |
| Imaging of optic nerve | 284 | $9,334 | $30 |
| Removal of cataract with insertion of prosthetic lens | 14 | $8,898 | $494 |
| Return visit (30+ min) | 74 | $8,557 | $108 |
| Established patient complete exam of visual system | 47 | $5,598 | $102 |
| Exam of the internal drainage system of eye | 91 | $2,441 | $25 |
| Photography of the retina | 40 | $1,291 | $31 |
| Measurement of corneal curvature and depth of eye | 29 | $1,117 | $39 |
| Ultrasound scan of cornea to determine thickness | 55 | $557 | $10 |
2021: 11 services
| Established patient problem focused exam of visual system | 316 | $57,584 | $77 |
| Exam of visual field with extended testing | 266 | $16,592 | $59 |
| New patient visit (45+ min) | 76 | $10,575 | $139 |
| Established patient complete exam of visual system | 87 | $9,976 | $100 |
| Removal of cataract with insertion of prosthetic lens | 14 | $9,328 | $491 |
| Imaging of optic nerve | 260 | $9,183 | $32 |
| Return visit (30+ min) | 63 | $7,698 | $117 |
| Exam of the internal drainage system of eye | 77 | $2,378 | $27 |
| Measurement of corneal curvature and depth of eye | 35 | $1,833 | $52 |
| Photography of the retina | 55 | $1,824 | $33 |
| Ultrasound scan of cornea to determine thickness | 52 | $575 | $11 |
2020: 10 services
| Established patient problem focused exam of visual system | 261 | $43,380 | $76 |
| Established patient complete exam of visual system | 109 | $14,573 | $106 |
| Exam of visual field with extended testing | 204 | $12,855 | $58 |
| Removal of cataract with insertion of prosthetic lens | 19 | $11,870 | $475 |
| New patient visit (45+ min) | 54 | $7,583 | $140 |
| Imaging of optic nerve | 177 | $6,305 | $33 |
| Photography of the retina | 52 | $1,965 | $38 |
| Measurement of corneal curvature and depth of eye | 28 | $1,625 | $58 |
| Exam of the internal drainage system of eye | 57 | $1,603 | $27 |
| Ultrasound scan of cornea to determine thickness | 32 | $350 | $11 |
2019: 11 services
| Established patient problem focused exam of visual system | 319 | $53,500 | $78 |
| Established patient complete exam of visual system | 153 | $20,667 | $108 |
| Removal of cataract with insertion of prosthetic lens | 20 | $17,115 | $611 |
| Exam of visual field with extended testing | 242 | $16,159 | $62 |
| New patient visit (45+ min) | 80 | $10,583 | $132 |
| Imaging of optic nerve | 221 | $8,084 | $33 |
| Photography of the retina | 80 | $3,712 | $45 |
| Measurement of corneal curvature and depth of eye | 41 | $2,993 | $67 |
| Exam of the internal drainage system of eye | 96 | $2,602 | $26 |
| Ultrasound scan of cornea to determine thickness | 74 | $826 | $11 |
| Imaging of retina | 12 | $482 | $37 |
2018: 10 services
| Established patient problem focused exam of visual system | 186 | $33,498 | $76 |
| Established patient complete exam of visual system | 115 | $17,894 | $113 |
| Exam of visual field with extended testing | 161 | $10,892 | $62 |
| New patient visit (45+ min) | 55 | $7,759 | $141 |
| Imaging of optic nerve | 133 | $4,653 | $33 |
| Photography of the retina | 72 | $3,646 | $50 |
| New patient visit (60+ min) | 15 | $2,728 | $182 |
| Exam of the internal drainage system of eye | 72 | $1,943 | $25 |
| Measurement of corneal curvature and depth of eye | 13 | $924 | $71 |
| Ultrasound scan of cornea to determine thickness | 62 | $858 | $14 |
2017: 10 services
| Established patient complete exam of visual system | 176 | $24,761 | $111 |
| Established patient problem focused exam of visual system | 186 | $23,080 | $73 |
| Exam of visual field with extended testing | 130 | $8,256 | $57 |
| Photography of the retina | 87 | $5,659 | $64 |
| New patient visit (45+ min) | 39 | $5,136 | $132 |
| Imaging of optic nerve | 115 | $3,695 | $31 |
| New patient visit (60+ min) | 20 | $3,560 | $178 |
| Exam of the internal drainage system of eye | 62 | $1,646 | $25 |
| Return visit (30+ min) | 12 | $642 | $54 |
| Ultrasound scan of cornea to determine thickness | 41 | $554 | $13 |
2016: 12 services
| Established patient complete exam of visual system | 120 | $15,219 | $96 |
| Established patient problem focused exam of visual system | 120 | $13,538 | $68 |
| Removal of cataract with insertion of prosthetic lens | 12 | $10,329 | $608 |
| Exam of visual field with extended testing | 84 | $4,918 | $49 |
| New patient visit (45+ min) | 28 | $3,739 | $134 |
| New patient visit (60+ min) | 20 | $3,736 | $187 |
| Imaging of optic nerve | 86 | $2,811 | $32 |
| Photography of the retina | 28 | $2,239 | $77 |
| Return visit (30+ min) | 18 | $1,719 | $95 |
| Exam of the internal drainage system of eye | 59 | $1,542 | $25 |
| Short return visit (20+ min) | 17 | $1,251 | $63 |
| Ultrasound scan of cornea to determine thickness | 42 | $576 | $14 |
2015: 13 services
| Established patient complete exam of visual system | 100 | $12,262 | $116 |
| Established patient problem focused exam of visual system | 56 | $5,683 | $84 |
| Exam of visual field with extended testing | 72 | $4,426 | $61 |
| Photography of the retina | 39 | $3,140 | $81 |
| New patient visit (45+ min) | 21 | $3,089 | $147 |
| Return visit (30+ min) | 27 | $2,779 | $99 |
| Imaging of optic nerve | 30 | $1,246 | $42 |
| Established patient complete exam of visual system | 13 | $855 | $66 |
| Established patient problem focused exam of visual system | 19 | $852 | $45 |
| Exam of the internal drainage system of eye | 31 | $791 | $26 |
| Measurement of corneal curvature and depth of eye | 24 | $523 | $21 |
| Exam of visual field with extended testing | 19 | $442 | $23 |
| Ultrasound scan of cornea to determine thickness | 22 | $301 | $14 |
2014: 2 services
| Established patient problem focused exam of visual system | 23 | $1,182 | $49 |
| Measurement of corneal curvature and depth of eye | 21 | $617 | $29 |
Medicaid work
$3,243 in 2024
Medicaid paid $3,243 for 154 billed services this clinician did in 2024, up to 21 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 154 | $3,243 |
| 2024 | 154 | 1 | 21 | $3,243 |
| 2023 | 188 | 1 | 23 | $4,287 |
| 2022 | 218 | 1 | 25 | $5,177 |
| 2021 | 164 | 2 | 21 | $3,355 |
| 2020 | 99 | 1 | 17 | $1,832 |
| 2019 | 60 | 1 | 17 | $825 |
See the largest Medicaid services in earlier years
2023
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 188 | $4,287 |
2022
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 218 | $5,177 |
2021
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 152 | $3,105 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 12 | $250 |
2020
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 99 | $1,832 |
2019
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 60 | $825 |
Drugs they prescribed that Part D paid
$498,076
Pharmacies billed $498,076 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 3,232) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
1,750 generic and 1,482 brand-name prescriptions · $498,076 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vyzulta | 199 | $86,186 | $433 |
| Rhopressa | 124 | $65,885 | $531 |
| Lumigan | 135 | $65,763 | $487 |
| Rocklatan | 72 | $32,748 | $455 |
| Alphagan P | 52 | $28,306 | $544 |
See all 31 drugs
| Vyzulta | 199 | $86,186 | $433 |
| Rhopressa | 124 | $65,885 | $531 |
| Lumigan | 135 | $65,763 | $487 |
| Rocklatan | 72 | $32,748 | $455 |
| Alphagan P | 52 | $28,306 | $544 |
| Azopt | 34 | $22,665 | $667 |
| Combigan | 31 | $17,353 | $560 |
| Dorzolamide-Timolol | 100 | $16,215 | $162 |
| Brimonidine | 326 | $15,612 | $48 |
| Simbrinza | 35 | $12,854 | $367 |
| Brinzolamide | 58 | $12,210 | $211 |
| Zioptan | 17 | $10,851 | $638 |
| Timolol Maleate | 16 | $10,652 | $666 |
| Travoprost | 45 | $10,575 | $235 |
| Timolol Maleate | 416 | $9,666 | $23 |
| Restasis | 11 | $9,090 | $826 |
| Dorzolamide-Timolol | 363 | $9,076 | $25 |
| Xalatan | 14 | $9,059 | $647 |
| Latanoprost | 614 | $8,864 | $14 |
| Tafluprost | 29 | $7,706 | $266 |
| Iyuzeh | 14 | $6,409 | $458 |
| Prednisolone Acetate | 125 | $4,532 | $36 |
| Pilocarpine | 58 | $3,584 | $62 |
| Brimonidine Tartrate-Timolol | 30 | $2,758 | $92 |
| Dorzolamide | 93 | $1,839 | $20 |
| Betaxolol | 26 | $1,722 | $66 |
| Ketorolac Tromethamine | 41 | $653 | $16 |
| Ofloxacin | 54 | $557 | $10 |
| Atropine Sulfate | 11 | $453 | $41 |
| Moxifloxacin | 18 | $344 | $19 |
| Erythromycin | 25 | $221 | $9 |
Year by year
| 2024 | 3,232 | 442 | 0% (0) | 46% | $498,076 |
| 2023 | 3,080 | 447 | 0% (0) | 48% | $553,186 |
| 2022 | 2,780 | 435 | 0% (0) | 51% | $494,184 |
| 2021 | 2,448 | 402 | 0% (0) | 57% | $462,965 |
| 2020 | 1,649 | 333 | 0% (0) | 53% | $266,381 |
| 2019 | 1,227 | 240 | 0% (0) | 49% | $180,022 |
| 2018 | 996 | 184 | 0% (0) | 43% | $108,370 |
| 2017 | 928 | 176 | 0% (0) | 45% | $88,412 |
| 2016 | 910 | 271 | 0% (0) | 43% | $94,740 |
| 2015 | 2,528 | 455 | 0% (0) | 51% | $262,467 |
| 2014 | 1,009 | 330 | 0% (0) | None | $80,354 |
| 2013 | 292 | 59 | 0% (0) | None | $11,474 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 28 drugs
| Lumigan | 162 | $92,675 | $572 |
| Rhopressa | 143 | $77,326 | $541 |
| Vyzulta | 156 | $66,389 | $426 |
| Rocklatan | 73 | $42,992 | $589 |
| Alphagan P | 69 | $38,079 | $552 |
| Brinzolamide | 62 | $23,457 | $378 |
| Azopt | 36 | $23,169 | $644 |
| Combigan | 27 | $17,683 | $655 |
| Simbrinza | 36 | $14,758 | $410 |
| Dorzolamide-Timolol | 84 | $14,286 | $170 |
| Latanoprost | 621 | $14,227 | $23 |
| Timolol Maleate | 384 | $12,314 | $32 |
| Dorzolamide-Timolol | 350 | $12,220 | $35 |
| Zioptan | 17 | $9,186 | $540 |
| Brimonidine Tartrate-Timolol | 29 | $8,667 | $299 |
| Tafluprost | 26 | $8,593 | $331 |
| Travoprost | 42 | $8,065 | $192 |
| Brimonidine | 262 | $7,891 | $30 |
| Methazolamide | 11 | $5,031 | $457 |
| Pilocarpine | 67 | $4,951 | $74 |
| Prednisolone Acetate | 111 | $4,690 | $42 |
| Dorzolamide | 95 | $4,421 | $47 |
| Betaxolol | 42 | $2,892 | $69 |
| Ketorolac Tromethamine | 28 | $1,002 | $36 |
| Ofloxacin | 39 | $538 | $14 |
| Atropine Sulfate | 11 | $443 | $40 |
| Moxifloxacin | 12 | $274 | $23 |
| Erythromycin | 13 | $107 | $8 |
2022: 26 drugs
| Lumigan | 190 | $100,317 | $528 |
| Rhopressa | 128 | $60,067 | $469 |
| Alphagan P | 80 | $38,174 | $477 |
| Vyzulta | 83 | $34,532 | $416 |
| Azopt | 50 | $32,582 | $652 |
| Rocklatan | 74 | $31,500 | $426 |
| Zioptan | 45 | $21,099 | $469 |
| Brinzolamide | 52 | $19,655 | $378 |
| Simbrinza | 49 | $17,082 | $349 |
| Latanoprost | 562 | $14,605 | $26 |
| Timolol Maleate | 367 | $12,277 | $33 |
| Combigan | 19 | $12,201 | $642 |
| Dorzolamide-Timolol | 273 | $11,863 | $43 |
| Travoprost | 43 | $10,213 | $238 |
| Dorzolamide-Timolol | 49 | $9,245 | $189 |
| Travatan Z | 20 | $8,949 | $447 |
| Brimonidine Tartrate-Timolol | 30 | $8,313 | $277 |
| Brimonidine | 215 | $5,794 | $27 |
| Prednisolone Acetate | 123 | $5,587 | $45 |
| Dorzolamide | 72 | $3,034 | $42 |
| Flurbiprofen | 41 | $2,739 | $67 |
| Pilocarpine | 31 | $2,102 | $68 |
| Betaxolol | 25 | $2,025 | $81 |
| Ketorolac Tromethamine | 22 | $809 | $37 |
| Atropine Sulfate | 19 | $777 | $41 |
| Ofloxacin | 47 | $688 | $15 |
2021: 28 drugs
| Lumigan | 191 | $88,815 | $465 |
| Azopt | 95 | $53,756 | $566 |
| Rhopressa | 120 | $50,463 | $421 |
| Alphagan P | 98 | $45,413 | $463 |
| Vyzulta | 49 | $24,177 | $493 |
| Combigan | 43 | $20,130 | $468 |
| Zioptan | 38 | $19,430 | $511 |
| Rocklatan | 39 | $17,295 | $443 |
| Latanoprost | 532 | $15,943 | $30 |
| Timolol Maleate | 308 | $15,043 | $49 |
| Dorzolamide-Timolol | 241 | $11,439 | $47 |
| Timoptic Ocudose | 13 | $11,185 | $860 |
| Travatan Z | 19 | $10,033 | $528 |
| Restasis | 11 | $9,681 | $880 |
| Dorzolamide-Timolol | 33 | $8,647 | $262 |
| Brimonidine | 202 | $8,344 | $41 |
| Simbrinza | 20 | $7,274 | $364 |
| Cosopt Pf | 18 | $6,319 | $351 |
| Travoprost | 19 | $6,196 | $326 |
| Prednisolone Acetate | 102 | $4,161 | $41 |
| Dorzolamide | 48 | $2,878 | $60 |
| Pilocarpine | 32 | $2,177 | $68 |
| Flurbiprofen | 21 | $1,724 | $82 |
| Ketorolac Tromethamine | 24 | $1,203 | $50 |
| Betaxolol | 19 | $1,102 | $58 |
| Atropine Sulfate | 12 | $558 | $46 |
| Ofloxacin | 26 | $391 | $15 |
| Erythromycin | 11 | $136 | $12 |
2020: 24 drugs
| Lumigan | 104 | $45,575 | $438 |
| Rhopressa | 86 | $40,447 | $470 |
| Azopt | 60 | $26,583 | $443 |
| Alphagan P | 65 | $22,561 | $347 |
| Combigan | 43 | $17,796 | $414 |
| Vyzulta | 36 | $16,556 | $460 |
| Latanoprost | 327 | $10,284 | $31 |
| Rocklatan | 26 | $9,791 | $377 |
| Travatan Z | 20 | $9,616 | $481 |
| Timolol Maleate | 213 | $7,746 | $36 |
| Dorzolamide-Timolol | 39 | $7,174 | $184 |
| Dorzolamide-Timolol | 105 | $6,356 | $61 |
| Simbrinza | 16 | $5,782 | $361 |
| Zioptan | 12 | $4,627 | $386 |
| Travoprost | 13 | $4,571 | $352 |
| Prednisolone Acetate | 114 | $4,414 | $39 |
| Durezol | 17 | $3,832 | $225 |
| Brimonidine | 100 | $3,017 | $30 |
| Cosopt Pf | 12 | $2,548 | $212 |
| Dorzolamide | 65 | $2,455 | $38 |
| Ketorolac Tromethamine | 35 | $1,591 | $45 |
| Pilocarpine | 17 | $1,570 | $92 |
| Flurbiprofen | 30 | $1,484 | $49 |
| Ofloxacin | 42 | $595 | $14 |
2019: 17 drugs
| Rhopressa | 124 | $47,174 | $380 |
| Lumigan | 48 | $21,002 | $438 |
| Alphagan P | 44 | $17,794 | $404 |
| Azopt | 37 | $14,738 | $398 |
| Travatan Z | 16 | $9,728 | $608 |
| Latanoprost | 287 | $8,851 | $31 |
| Simbrinza | 27 | $8,188 | $303 |
| Combigan | 20 | $7,500 | $375 |
| Dorzolamide-Timolol | 73 | $5,220 | $72 |
| Brimonidine | 76 | $3,950 | $52 |
| Dorzolamide-Timolol | 22 | $3,341 | $152 |
| Timolol Maleate | 164 | $3,194 | $19 |
| Prednisolone Acetate | 74 | $3,057 | $41 |
| Dorzolamide | 44 | $2,884 | $66 |
| Ketorolac Tromethamine | 45 | $1,871 | $42 |
| Pilocarpine | 11 | $1,234 | $112 |
| Ofloxacin | 35 | $664 | $19 |
2018: 18 drugs
| Alphagan P | 48 | $14,462 | $301 |
| Lumigan | 35 | $13,282 | $379 |
| Azopt | 29 | $10,246 | $353 |
| Travatan Z | 24 | $7,495 | $312 |
| Simbrinza | 27 | $7,421 | $275 |
| Rhopressa | 20 | $7,117 | $356 |
| Combigan | 19 | $6,997 | $368 |
| Latanoprost | 260 | $6,356 | $24 |
| Brimonidine | 85 | $6,008 | $71 |
| Timolol Maleate | 150 | $3,367 | $22 |
| Cosopt | 11 | $2,137 | $194 |
| Prednisolone Acetate | 47 | $1,905 | $41 |
| Acetazolamide | 12 | $1,733 | $144 |
| Dorzolamide | 60 | $1,699 | $28 |
| Dorzolamide-Timolol | 52 | $1,437 | $28 |
| Pilocarpine | 17 | $1,347 | $79 |
| Ketorolac Tromethamine | 21 | $921 | $44 |
| Ofloxacin | 23 | $314 | $14 |
2017: 15 drugs
| Travatan Z | 48 | $11,959 | $249 |
| Brimonidine | 86 | $11,533 | $134 |
| Alphagan P | 36 | $10,690 | $297 |
| Lumigan | 28 | $10,208 | $365 |
| Combigan | 41 | $8,461 | $206 |
| Azopt | 23 | $7,276 | $316 |
| Latanoprost | 285 | $6,087 | $21 |
| Simbrinza | 19 | $3,977 | $209 |
| Pilocarpine | 37 | $2,221 | $60 |
| Prednisolone Acetate | 45 | $2,061 | $46 |
| Dorzolamide-Timolol | 58 | $1,624 | $28 |
| Timolol Maleate | 120 | $1,393 | $12 |
| Dorzolamide | 30 | $614 | $20 |
| Ketorolac Tromethamine | 12 | $580 | $48 |
| Ofloxacin | 12 | $162 | $13 |
2016: 15 drugs
| Travatan Z | 59 | $16,265 | $276 |
| Azopt | 45 | $15,105 | $336 |
| Lumigan | 44 | $13,137 | $299 |
| Brimonidine | 75 | $9,051 | $121 |
| Alphagan P | 15 | $6,733 | $449 |
| Latanoprost | 259 | $4,188 | $16 |
| Combigan | 20 | $4,048 | $202 |
| Simbrinza | 13 | $3,058 | $235 |
| Prednisolone Acetate | 44 | $2,955 | $67 |
| Dorzolamide-Timolol | 92 | $1,958 | $21 |
| Timolol Maleate | 117 | $1,377 | $12 |
| Dorzolamide | 22 | $731 | $33 |
| Olopatadine | 11 | $514 | $47 |
| Ketorolac Tromethamine | 11 | $495 | $45 |
| Ofloxacin | 15 | $314 | $21 |
2015: 20 drugs
| Azopt | 172 | $50,577 | $294 |
| Travatan Z | 187 | $38,047 | $203 |
| Lumigan | 140 | $33,123 | $237 |
| Brimonidine | 181 | $23,873 | $132 |
| Combigan | 83 | $19,408 | $234 |
| Alphagan P | 48 | $13,814 | $288 |
| Latanoprost | 729 | $11,764 | $16 |
| Zioptan | 30 | $7,977 | $266 |
| Timolol Maleate | 272 | $6,257 | $23 |
| Prednisolone Acetate | 93 | $6,173 | $66 |
| Dorzolamide-Timolol | 247 | $5,854 | $24 |
| Simbrinza | 31 | $5,715 | $184 |
| Patanol | 23 | $5,492 | $239 |
| Restasis | 13 | $4,869 | $375 |
| Dorzolamide | 103 | $3,454 | $34 |
| Acetazolamide | 19 | $3,366 | $177 |
| Durezol | 19 | $2,837 | $149 |
| Pilocarpine | 11 | $1,573 | $143 |
| Methazolamide | 17 | $1,106 | $65 |
| Azelastine | 13 | $696 | $54 |
2014: 17 drugs
| Brimonidine | 87 | $8,805 | $101 |
| Travatan Z | 45 | $8,717 | $194 |
| Lumigan | 34 | $8,675 | $255 |
| Azopt | 42 | $8,288 | $197 |
| Restasis | 16 | $5,377 | $336 |
| Latanoprost | 263 | $4,895 | $19 |
| Prednisolone Acetate | 70 | $4,472 | $64 |
| Combigan | 24 | $4,111 | $171 |
| Alphagan P | 24 | $3,727 | $155 |
| Dorzolamide-Timolol | 112 | $3,220 | $29 |
| Durezol | 17 | $2,579 | $152 |
| Methazolamide | 14 | $1,781 | $127 |
| Vigamox | 15 | $1,669 | $111 |
| Timolol Maleate | 94 | $1,371 | $15 |
| Dorzolamide | 42 | $1,196 | $28 |
| Ketorolac Tromethamine | 16 | $339 | $21 |
| Neomycin-Polymyxin-Dexameth | 11 | $233 | $21 |
2013: 5 drugs
| Brimonidine | 42 | $3,516 | $84 |
| Latanoprost | 111 | $1,825 | $16 |
| Dorzolamide-Timolol | 53 | $1,616 | $30 |
| Prednisolone Acetate | 11 | $316 | $29 |
| Timolol Maleate | 18 | $168 | $9 |
Money from drug and device companies
$413 in 2025
| 2025 | 5 | 8 | None | $413 |
| 2024 | 5 | 19 | None | $541 |
| 2023 | 5 | 19 | None | $697 |
| 2022 | 2 | 6 | None | $129 |
| 2021 | 3 | 6 | None | $210 |
| 2020 | 3 | 6 | None | $114 |
| 2019 | 2 | 11 | None | $146 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alcon Vision | Hydrus Microstent | $179 | 2 payments
|
| Biotissue Holdings | None | $129 | 1 payment
|
| Thea Pharma | Iyuzeh | $43 | 2 payments
|
| Abbvie | Lumigan | $43 | 2 payments
|
| Bausch & Lomb Americas | Vyzulta | $18 | 1 payment
|
See all 8 published payments
| Bausch & Lomb Americas | Meals · 2025-11-05 | Vyzulta | $18 |
| Biotissue Holdings | Meals · 2025-10-09 | None | $129 |
| Thea Pharma | Meals · 2025-08-25 | Iyuzeh | $22 |
| Alcon Vision | Meals · 2025-06-17 | Hydrus Microstent | $159 |
| Alcon Vision | Meals · 2025-05-15 | Rocklatan | $20 |
| Abbvie | Meals · 2025-04-22 | Lumigan | $22 |
| Thea Pharma | Meals · 2025-04-07 | Iyuzeh | $21 |
| Abbvie | Meals · 2025-03-06 | Lumigan | $21 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $541
| Alcon Vision | Rocklatan | $204 | 14 payments
|
| Sight Sciences | Omni Surgical System | $174 | 2 payments
|
| RxSight | Rxsight Contact Lens | $114 | 1 payment
|
| Abbvie | Lumigan | $27 | 1 payment
|
| Thea Pharma | Iyuzeh | $22 | 1 payment
|
2023: $697
| Alcon Vision | Rocklatan | $393 | 15 payments
|
| Genentech USA | None | $149 | 1 payment
|
| Sight Sciences | Omni Surgical System | $110 | 1 payment
|
| Bausch & Lomb Americas | Vyzulta | $23 | 1 payment
|
| Abbvie | Lumigan | $23 | 1 payment
|
2022: $129
| Bausch & Lomb Americas | Vyzulta | $89 | 4 payments
|
| Alcon Vision | Simbrinza | $40 | 2 payments
|
2021: $210
| Allergan | Xen Glaucoma Treatment System | $171 | 4 payments
|
| Bausch & Lomb a division of Bausch Health US | Vyzulta | $21 | 1 payment
|
| Johnson & Johnson Surgical Vision | Tecnis Iol | $18 | 1 payment
|
2020: $114
| Allergan | Durysta | $73 | 4 payments
|
| Sun Pharmaceutical Industries | Xelpros | $21 | 1 payment
|
| Carl Zeiss Meditec AG | None Specified | $19 | 1 payment
|
2019: $146
| Allergan | Lumigan | $121 | 10 payments
|
| Bausch & Lomb a division of Bausch Health US | Vyzulta | $25 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1235455197
- Licence
- CA A118454California A118454: Current · expires 2027-03-31
- Trained
- New York University School of Medicine, 2010
- Group
- A Sydney Williams and Associates Inc · Thomas Tayeri M D Inc
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 101 S San Mateo Dr Ste 306, San Mateo, CA, 94401
- NPI first listed
- 2010-04-15
- NPI last updated
- 2024-08-08
- NPI record certified
- 2024-08-08
This is when the NPI record was last certified, not a medical board exam.